Form 8-K · Current Report · Filed 2025-11-17
Ionis Pharmaceuticals Announces $770M Private Offering of Convertible Senior Notes
Ionis Pharmaceuticals, Inc. has announced the completion of a private offering of $770.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2030. The proceeds from this offering will be used to repurchase existing 2026 Convertible Notes and for general corporate purposes. The Notes are convertible under certain conditions and are subject to specified events of default. The announcement was made via press releases on November 11 and November 12, 2025.
- Filer
- Ionis Pharmaceuticals Inc. IONS · NASDAQ
- Filed
- Accession
- 0001193125-25-284609
- CIK
- 0000874015
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Entry into a Material Definitive Agreement
Creation of a Direct Financial Obligation
Unregistered Sales of Equity Securities
Other Events
Market reaction
Close before filing
$71.55
Next session
+4.1%
Since filing
-27.6%
Latest close
$51.77
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from IONS reporting the same item, with the next session's move:
About Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing RNA-targeted therapeutics. The primary mission of Ionis is to harness its expertise in antisense oligonucleotide technology to address complex genetic disorders. Ionis is pioneering in the field of RNA-targeted drug discovery, aiming to treat a wide range of diseases, including neurological, cardiovascular, metabolic, and cancer-related conditions. Notably, the company has a robust pipeline of drugs in various stages of development and partnerships with leading pharmaceutical companies to expand the reach and impact of its therapeutic discoveries. As an innovative entity in the biotechnology sector, Ionis Pharmaceuticals plays a significant role in advancing medical treatments that target the underlying genetic causes of diseases, thereby offering new hope and potential solutions to patients worldwide. Its advancements contribute substantially to the growth and evolution of personalized medicine, emphasizing the importance of genetic research in modern healthcare.
Never miss another IONS filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.